Artikler med mandater om offentlig tilgang - Evan J. LipsonLes mer
Ikke tilgjengelig noe sted: 1
Sex-dependent effects in the aged melanoma tumor microenvironment influence invasion and resistance to targeted therapy
Y Chhabra, ME Fane, S Pramod, L Hüser, DJ Zabransky, V Wang, A Dixit, ...
Cell 187 (21), 6016-6034. e25, 2024
Mandater: Howard Hughes Medical Institute
Tilgjengelige et eller annet sted: 69
Detection of circulating tumor DNA in early-and late-stage human malignancies
C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ...
Science translational medicine 6 (224), 224ra24-224ra24, 2014
Mandater: US National Institutes of Health, Wellcome Trust, Government of Italy
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
SL Topalian, M Sznol, DF McDermott, HM Kluger, RD Carvajal, ...
Journal of clinical oncology 32 (10), 1020-1030, 2014
Mandater: US National Institutes of Health
Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma
HA Tawbi, D Schadendorf, EJ Lipson, PA Ascierto, L Matamala, ...
New England Journal of Medicine 386 (1), 24-34, 2022
Mandater: US National Institutes of Health
PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma
PT Nghiem, S Bhatia, EJ Lipson, RR Kudchadkar, NJ Miller, L Annamalai, ...
New England Journal of Medicine 374 (26), 2542-2552, 2016
Mandater: US National Institutes of Health
Evolutionary dynamics of cancer in response to targeted combination therapy
I Bozic, JG Reiter, B Allen, T Antal, K Chatterjee, P Shah, YS Moon, ...
elife 2, e00747, 2013
Mandater: US National Institutes of Health, Austrian Science Fund
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma
EJ Lipson, CG Drake
Clinical cancer research 17 (22), 6958-6962, 2011
Mandater: US National Institutes of Health
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody
EJ Lipson, WH Sharfman, CG Drake, I Wollner, JM Taube, RA Anders, ...
Clinical Cancer Research 19 (2), 462-468, 2013
Mandater: US National Institutes of Health
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
FB Cortazar, KA Marrone, ML Troxell, KM Ralto, MP Hoenig, JR Brahmer, ...
Kidney international 90 (3), 638-647, 2016
Mandater: US National Institutes of Health
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
L Heinzerling, PA Ott, FS Hodi, AN Husain, A Tajmir-Riahi, H Tawbi, ...
Journal for immunotherapy of cancer 4, 1-11, 2016
Mandater: US National Institutes of Health
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
CG Drake, EJ Lipson, JR Brahmer
Nature reviews Clinical oncology 11 (1), 24-37, 2014
Mandater: US National Institutes of Health
PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus, and overall survival
EJ Lipson, JG Vincent, M Loyo, LT Kagohara, BS Luber, H Wang, H Xu, ...
Cancer immunology research 1 (1), 54-63, 2013
Mandater: US National Institutes of Health
Cardiovascular toxicities associated with immune checkpoint inhibitors
JR Hu, R Florido, EJ Lipson, J Naidoo, R Ardehali, CG Tocchetti, AR Lyon, ...
Cardiovascular research 115 (5), 854-868, 2019
Mandater: US National Institutes of Health
Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy
P Nghiem, S Bhatia, EJ Lipson, WH Sharfman, RR Kudchadkar, AS Brohl, ...
Journal of Clinical Oncology 37 (9), 693-702, 2019
Mandater: US National Institutes of Health, A*Star, Singapore
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
LC Cappelli, AK Gutierrez, AN Baer, J Albayda, RL Manno, U Haque, ...
Annals of the rheumatic diseases 76 (1), 43-50, 2017
Mandater: US National Institutes of Health
Antagonists of PD-1 and PD-L1 in cancer treatment
EJ Lipson, PM Forde, HJ Hammers, LA Emens, JM Taube, SL Topalian
Seminars in oncology 42 (4), 587-600, 2015
Mandater: US National Institutes of Health
Tumor regression and allograft rejection after administration of anti–PD-1
EJ Lipson, SM Bagnasco, J Moore Jr, S Jang, MJ Patel, AA Zachary, ...
New England Journal of Medicine 374 (9), 896-898, 2016
Mandater: US National Institutes of Health
Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET/CT imaging in patients with advanced melanoma
SY Cho, EJ Lipson, HJ Im, SP Rowe, EM Gonzalez, A Blackford, ...
Journal of Nuclear Medicine 58 (9), 1421-1428, 2017
Mandater: US National Institutes of Health
Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade
EJ Lipson, VE Velculescu, TS Pritchard, M Sausen, DM Pardoll, ...
Journal for immunotherapy of cancer 2, 1-7, 2014
Mandater: US National Institutes of Health
Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma
ND Gross, DM Miller, NI Khushalani, V Divi, ES Ruiz, EJ Lipson, F Meier, ...
New England Journal of Medicine 387 (17), 1557-1568, 2022
Mandater: US National Institutes of Health
Informasjon om publisering og finansiering fastsettes automatisk av et datamaskinprogram